Novel S-nitrosothiols have potential therapeutic uses for cystic fibrosis

Current Pharmaceutical Design

Volumn 19, Issue 19, 2013, Pages 3509-3520

  Zaman, Khalequz ^a   Fraser Butler, Maya ^a   Bennett, Deric ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

CFTR; Cystic fibrosis; Molecular therapy; S nitrosothiols; S nitrosylation

Indexed keywords

ADENOVIRUS VECTOR; ANTIINFLAMMATORY AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; LANCOVUTIDE; LENTIVIRUS VECTOR; MUCOLYTIC AGENT; MUTANT PROTEIN; PANCREAS ENZYME; S NITROSOGLUTATHIONE; S NITROSOTHIOL; SODIUM CHLORIDE;

ALLELE; APICAL MEMBRANE; ARTICLE; CELL MATURATION; CELL SURFACE; CYSTIC FIBROSIS; DISEASE COURSE; DRUG HALF LIFE; ENZYME REPLACEMENT; GENE TARGETING; GENE THERAPY; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; INTRACELLULAR SIGNALING; LUNG ALVEOLUS CELL; LUNG DISEASE; LUNG FUNCTION; LUNG TRANSPLANTATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; RESPIRATORY EPITHELIUM; ANIMAL; CELL MEMBRANE; DRUG EFFECT; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; GENETICS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; PROTEIN TRANSPORT; REVIEW;

ANIMALS; CELL MEMBRANE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM-ASSOCIATED DEGRADATION; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN TRANSPORT; S-NITROSOTHIOLS;

EID: 84886747410     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990319     Document Type: Article

References (153)

1. Boucher RC. An overview of the pathogenesis of cystic fibrosis lung disease. Adv Drug Deliv Rev 2002; 54: 1359-71.
2. Quinton PM. Physiological basis of cystic fibrosis: a historical perspective. Physiol Rev 1999; 79: S3-22.
3. Ratjen F, Grasemann H. New therapies in cystic fibrosis. Curr Pharm Des 2012; 18: 614-27.
4. Ratjen FA. Cystic Fibrosis: Pathogenesis and future treatment stratergies. Respir Care 2009; 54: 595-605.
5. Davis PB. Cystic Fibrosis since 1938. Am J Respir Crit Care Med 2006; 173: 475-82.
6. Tsui LC, Durie P. Genotype and phenotype in cystic fibrosis. Hosp Pract 1997; 32: 115-34.
7. Pier GB. The challenges and promises of new therapies for cystic fibrosis. J Exp Med 2012; 209: 1235-9.
8. Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem 2008; 77: 701-26.
9. Guggino WB, Stanton BA. New insights into cystic fibrosis: molecular switches that regulate CFTR. Nat Rev Mol Cell Biol 2006; 7: 426-36.
10. Riordan JR, Rommena JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066-73.
11. Collins FS. Cystic fibrosis: moleculat biology and therapeutic implications. Science 1992; 256: 774-9.
12. Mogayzel PJ, Flume PA. Update in cystic fibrosis 2009. Am J Respir Crit Care Med 2010; 181: 539-44.
13. Rowe SM, Borowitz DS, Burns JL, et al. Progress in cystic fibrosis and the CF therapeutics development network. Thorax 2012; 67: 882-90.
14. Edelman A, Fritsch J, Ollero M. Twenty years after cystic fibrosis gene identification: Where are we and what are we up to? Pathol Biol (Paris) 2011; 59: 131-3.
15. Kopito RR. Biosynthesis and degradation of CFTR. Physiol Rev 1999; 79(1 suppl): S167-72.
16. Skach WR. CFTR: New members join the fold. Cell 2006; 127: 673-5.
17. Younger JM, Fan CY, Chen L, Rosser MF, Patterson C, Cyr DM. Cystic fibrosis transmembrane conductance regulator as a model substrate to study endoplasmic reticulum protein quality control in mammalian cells. Methods Mol Biol 2005; 301: 293-303.
18. Meacham GC, Lu Z. King S, Sorscher E, Tousson A, Cyr DM. The Hdj-2/Hsc70 chaperone pair facilities early steps in CFTR biogenesis. EMBO J 1999; 18: 1492-505.
19. Grove DE, Rosser MF, Ren HY, Naren AP, Cyr DM. Mechanisms for rescue of correctable folding defects in CFTR ΔF508. Mol Biol Cell 2009; 20: 4059-69.
20. Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin proteasome pathway. Cell 1995; 83: 121-7.
21. Welch WJ, Brown CR. Influence of molecular and chemical chaperones on protein folding. Cell Stress Chaperones 1996; 1: 117-25.
22. Amaral MD. CFTR and Chaperones. J Mol Neurosci 2004; 23: 41-7
23. Amaral MD. Therpy through chaperones: sense or antisense? Cystic Fibrosis as a model disease. J Inherit Metab Dis 2006; 29: 477-87.
24. Rosser MF, Grove DE, Chen L, Cyr DM. Assembly and misassembly of cystic fibrosis transmembrane conductance regulator: folding defects caused by deletion of F508 occur before and after the calnexin-dependent association of membrane spanning domain (MSD)1 and MSD2. Mol Biol Cell 2008; 1911: 4570-9.
25. Amaral MD. Processing of CFTR traversing the cellular maze-how much CFTR needs to go through to avoid cystic fibrosis. Pediatric Pulmonol 2005; 39: 479-91.
26. Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 1995; 83: 121-7.
27. Meacham GC, Cyr DM. Isolation of CFTR. Chaperone complexes by co-immunoprecipitation. Methods Mol Med 2002; 70: 245-56.
28. Skach WR. Defects in processing and trafficking of the cystic fibrosis transmembrane conductance regulator. Kidney Int 2000; 57: 825-31.
29. Sato S, Ward CL, Krouse ME, Kopito RR. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis maturation. J Biol Chem 1996; 271: 635-8.
30. Ward C, Kopito R. Intracellular turnover of cystic fibrosis transmembrane conductance regulator. In efficient processing and rapid degradation of wild-type and mutant proteins. J Biol Chem 1994; 269: 25710-8.
31. Bertrand CA, Frizzell RA. The role of regulated CFTR trafficking in epithelial secretion. Am J Physiol Cell Physiol 2003; 285: C1-C18.
32. Farinha CM, Amaral MD. F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin. Mol Cell Biol 2005; 25: 5242-52.
33. Farinha CM, Noguerira P, Mendes F, Penque D, Amaral MD. The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp)40 cochaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70. Biochem J 2002; 366: 797-806.
34. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245: 1059-65.
35. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature sensitive. Nature 1992; 358: 761-4.
36. Hyde S, Gill DR, Higgins CF, et al. Correction of ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature 1993; 362: 250-5.
37. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992; 2: 21-5.
38. Rich DP, Couture LA, Cardoza LM, et al. Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Hum Gene Ther 1993; 4: 461-74.
39. Engelhard JF, Yankaskas JR, Ernst SA, et al. Submucosal glands are predominant site of CFTR expression in the human bronchus. Nat Genet 1992; 2: 240-8.
40. Engelhard JF, Zepeda M, Cohn JA, Yankaskas JR, Wilson JR. Expression of the cystic fibrosis gene in adult human lung. J Clin Invest 1994; 93: 737-47.
41. Wagner JA, Chao AC, Gardner P. Molecular strategies for therapy of cystic fibrosis. Ann Rev Pharmacol Toxicol 1995; 35: 257-76.
42. Regnis JA, Robinson M, Bailey DL, et al. Mucociliary clearance in patients with cystic fibrosis and normal subjects. Am J Respir Crit Care Med 1994; 150: 66-71.
43. Belcher CN, Vij N. Protein processing and inflammation signaling in cystic fibrosis: challenger and therapeutic strategies. Curr Mol Med 2010; 10: 82-94.
44. Vij N, Amoako MO, Mazur S, Zeitlin PL. CHOP transcription factor mediates IL-8 signaling in cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol 2008; 38: 176-84.
45. Drumm ML. What happens to deltaF508 in vivo. J Clin Invest 1999; 103: 1369-70.
46. Balch WE, Morimoto RI, Dillin A, Kelly JW. Adapting proteostasis for disease intervention. Science 2008; 319: 916-9.
47. Nichols DP, Konstan MW. Anti-inflammatory therapy for cystic fibroisis related lung disease. Clin Rev Allerg Immunol 2008; 35: 135-53.
48. Ribeiro CM, Paradiso AM, Schwab U, et al. Chronic airway infection/ inflammation induces a Ca2+i-dependent hyperinflammatory response in human cystic fibrosis airway epithelia. J Biol Chem 2005; 280: 17798-806.
49. Gao L, Kim KJ, Yankaskas JR, Forman HJ. Abnormal glutathione transport in cystic fibrosis airway epithelia. Am J Physiol 1999; 277: L113-8.
50. Brouillard F, Bouthier M, Leclerc T, Clement A, Baudouin-Legros M, Edelman A. NFkB mediates up-regulation of CFTR gene expression in Calu-3 cells by interleukin-1β. J Biol Chem 2001; 276: 9486-91.
51. Hampton TH, Ballok AF, Bomberger JM, et al. Does the ΔF508 CFTR mutation induce a proinflammatory response in human airway epithelial cells. Am J Physiol Regul Integr Comp Physiol 2012; 303: L509-18.
52. Koehler DR, Downey GP, Sweezey NB, Transwell AK. Lung inflammation as a therapeutic target in cystic fibrosis. Am J Respir Cell Mol Biol 2004; 31: 377-81.
53. Davis PB, Drumm ML, Konstan MW. State of an art: cystic fibrosis. Am J Resp Crit Care Med 1996; 154: 1229-56.
54. Carrabino S, Carpani D, Livraghi A, et al. Dysregulated interleukin-8 secretion and NF-kappaB activity in human cystic fibrosis nasal epithelial cells. J Cyst Fibros 2006; 5: 113-9.
55. Stecenko AA, King G, Torii K, et al. Dysregulated cytokine production in human cystic fibrosis bronchial epithelial cells. Inflammation 2001; 25: 145-55.
56. Perez A, Issler AC, Cotton CU, Kelley TJ, Verkman AS, Davis PB. CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am J Physiol Lung Cell Mol Physiol 2007; 292: L383-95.
57. Dinwiddie R. Anti-inflammatory therapy in cystic fibrosis. J Cyst Fibros 2005; 4: 45-8.
58. Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002; 23: 5-27.
59. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit care Med 1995; 151: 1075-82.
60. Ollero M, Brouillard F, Edelman A. Cystic fibrosis enters the proteomics scene: new answers to old questions. Proteomics 2006; 6: 4084-99
61. Ahner A, Zhang H, Frizzel RA, Brodsky JL. A genomic yeast screen identifies small heat shock proteins as regulators of CFTR degradation. Ped Pulmonol Abst 2005; 15: 195.
62. Kleizen B, Braakman I, de Jonge HR. Regulated trafficking of the CFTR chloride channel. Eur J Cell Biol 2000; 79: 544-56.
63. Sun F, Mi Z, Condliffe SB, et al. Chaperone displacement from mutant cystic fibrosis transmembrane conductance regulator restores its function in human airway epithelia. FASEB J 2008; 22: 3255-63.
64. Zeitlin PL, Diener-West M, Rubenstein RC, Boyle MP, Lee C, Brass-Ernst L. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 2002; 6: 119-26.
65. Bradbury NA. Focus on sodium 4-phenylbutyrate downregulates Hsc70 implications for intracellular trafficking of deltaF508 CFTR. Am J Physiol Cell Physiol 2000; 278: C257-8.
66. Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective ΔF508 CFTR cellular processing identified by high throughput screening. J Clin Invest 2005; 115: 2564-71.
67. Heda GD, Marino CR. Surface expression of the cystic fibrosis transmembrane conductance regulator mutant deltaF508 is markedly upregulated by combination treatment with sodium butyrate and low temperature. Biochem Biophys Res Commun 2000; 271: 659-64.
68. Andersson C, Roomans GM. Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX. Eur Respir J 2000; 15: 937-41.
69. Srivastava M, Eidelman O, Pollard HB. Pharmacogenomics of the cystic fibrosis transmembrane conductance regulator and the cystic fibrosis drug CPX using genome microarray analysis. Mol Med 1999; 5: 753-67.
70. Egan ME, Glockner-Pagel J, Ambrose CA, et al. Calcium-pump inhibitors induce functional surface expression of ΔF508 CFTR protein in cystic fibrosis epithelial cells. Nat Med 2002; 8: 485-92.
71. Grubb BR, Gabriel SE, Mengos A. et al. SERCA pump inhibitors do not correct biosynthetic arrest of deltaF508 CFTR in cystic fibrosis. Am J Respir Cell Mol Biol 2006; 343: 355-63.
72. Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 1997; 100: 2457-65.
73. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998; 157: 484-90.
74. Rubenstein RC. And Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508 CFTR homozygous cystic fibrosis patients: Partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998; 157: 484-90.
75. Rubenstein RC. Lyons BM. Sodium 4-phenylbutyrate downregulates Hsc70 expression by facilitating mRNA degradation. Am J Physiol Lung Cell Mol Physiol 2001; 281: L43-51.
76. Rubenstein RC, Zeitlin PL. Sodium 4-phenybutyrate downregulates Hsc70: Implications for intracellular trafficking of deltaF508 CFTR. Am J Physiol Cell Physiol 2000; 278: C259-67.
77. Basile A, Pascale M, Franceschelli S, et al. Matrine modulates Hsc70 levels and rescue ΔF508 CFTR. J Cell Physiol 2012; 227: 3317-23.
78. Zeitlin PL. Pharmacologic restoration on deltaF508 CFTR mediatred chloride current. Kidney Intl 2000; 57: 832-7.
79. Choo-Kang LR, Zeitlin PL. Induction of Hsp70 promotes deltaF508 CFTR trafficking. Am J Physiol Lung Cell Biol Physiol 2001; 281: L58-68.
80. - channel by butyrate and phenylbutyrate. Eur J Pharmacol 2001; 411: 255-60.
81. McGrath-Marrow SA, Stahl JL. G1 phase growth arrest and induction of p21 in IB3-1 cells treated with 4-sodium phenylbutyrate. J Pharmacol Exp Ther 2000; 294: 941-7.
82. Egan ME, Pearson M, Weiner SA, et al. Curcumin: a major constituent of turmeric corrects cystic fibrosis defects. Science 2004; 3045670: 600-2.
83. Lipecka J, Norez C, Bensalem N, et al. Rescue of deltaF508 CFTR (cystic fibrosis transmembrane conductance regulator) by curcumin: involvement of the keratin 18 network. J Pharmacol Exp Ther 2006; 317: 500-5.
84. Dragomir A, Bjorstad J, Hjelte L, Roomans GM. Curcumin does not stimulate cAMP mediated chloride transport in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 2004; 3222: 447-51.
85. - channels via a tyrosine kinase and protein phosphatase independent mechanism. Am J Physiol Cell Physiol 1997; 273: C747-53.
86. Collawn JF, Bebok Z, Matalon S. Search and Rescue: Finding ways to correct ΔF508 CFTR. Am J Respir Cell Mol Biol 2009; 40: 385-7.
87. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of a CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009; 106: 18825-30.
88. Wang Y, Loo TW, Bartlett MC, Clarke DM. Correctors promote maturation of cystic fibrosis transmembrane conductance regulator processing mutants by binding to the protein. J Biol Chem 2007; 16: 33247-51.
89. Van Goor F, Hadida S, Grootenhuls PD. VX-809 a CFTR corrector, increase the cell surface density of functional deltaF508 CFTR in pre-clinical models of cystic fibrosis. Pediatr Pulmonol 2009; 442: 154-5.
90. Clancy JP, Rowe SM, Accurso FJ, et al. A phase II randomized placebo-controlled clinical trial of four doses of VX-809 in CF patients homozygous for the deltaF508 CFTR mutation. Pediatr Pulmonol 2010; 453: 228.
91. Accurso F, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363: 1991-2003.
92. Suaud L, Li J, Jiang Q, Rubenstein RC, Kleyman TR. Genistein restores functional interactions between deltaF508 CFTR and ENaC in Xenopus oocytes. J Biol Chem 2002; 277: 8928-33.
93. Zeitlin P, Boyle M, Guggino W. A phase I trial intra-nasal Moli 1901 for cystic fibrosis. Chest 2005; 25: 143-9.
94. Grasemann H, Stehling F, Brunar H, et al. Inhalation of Moli 1901 in patients with cystic fibrosis. Chest 2007; 131: 1461-6.
95. Robinson M, Hemming A, Regnis J, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997; 52: 900-3.
96. Grasemann H, Ratjen F. Emerging therapies for cystic fibrosis lung disease. Expert Opinion on Emerging Drugs 2010; 15: 653-9.
97. Ballmann M, Von der Hardt H. Hypertonic saline and recombinant human DNase: a randomized cross-over pilot study in patients with cystic fibrosis. J Cyst Fibrosis 2002; 1: 35-7.
98. Robinson M, Daviskas E, Eberi S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999; 14: 678-85.
99. Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011; 38: 1071-80.
100. Accurso F, Moss RB, Wilmott RW, et al. Denufasol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am J Respir Crit Care Med 2011; 183: 627-34.
101. Gaston B, Doctor A, Singel D, Stamler JS. S-Nitrosothiol signaling in respiratory biology. Am J Respir Crit Care Med. 2006; 173: 1186-93.
102. Stamler JS, Toone E, Lipton S, Sucher N. (S)NO signals: translocation, regulation, and a consensus motif. Neuron 1997; 18: 691-6.
103. Lancaster J, Gaston B. NO and nitrosothiols: spatial confinement and free diffusion. Am J Physiol Lung Cell Mol Physiol 2004; 287: 465-6.
104. Hogg N, Singh R, Konorev E, Joseph J, Kalyanaraman B. 1997. SNitrosoglutathione as a substrate for a-glutamyl transpeptidse. Biochem J 1997; 323: 477-81.
105. Gaston B. Nitric oxide and thiol groups. Biochim Biophys Acta 1999; 1411: 323-33.
106. 2+. Am J Physiol Lung Cell Mol Physiol 2000; 278: 899-905.
107. Marshall H, Que L, Stamler JS, Gaston B. S-Nitrosothiols in lung inflammation. Therapeutic targets of airway inflammation, ed. A. Eissa, in Lung biology in health and disease. New York: Marcel Dekker Inc 2003; pp. 123-34.
108. Marozkina NV, Gaston B. S-nitrosylation signaling regulates cellular protein interactions. Biochim Biophys Acta 2012; 820: 722-9.
109. Yang Y, Loscalzo J. S-nitrosoprotein formation and localization in endothelial cells. Proc Natl Acad Sci USA 2005; 102: 117-22.
110. Que LG, Liu L, Whitehead GS, Gavett SH, Schwartz D. A, Stamler JS. Protection from experimental asthma by an endogenous bronchodilator. Science 2005; 308: 1618-21.
111. Jilling T, Haddad I, Cheng S, Matalon S. Nitric oxide inhibits heterologous CFTR expression in polarized epithelial cells. Am J Physiol 1999; 277: 89-96.
112. Kelley TJ, Drumm ML. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest 1998; 102: 1200-07.
113. Gaston B, Ratjen F, Vaughan JW, et al. Nitrogen redox balance in the cystic fibrosis airway: Effects of anti-pseudomonal therapy. Am J Respir Crit Care Med 2002; 165: 387-90.
114. Gaston B, Reilly J, Drazen JM, et al. Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc Natl Acad Sci USA 1993; 90: 10957-61.
115. Mannick J, Schonhoff C, Papeta N, et al. S-Nitrosylation of mitochondrial caspases. J Cell Biol 2001; 154: 1111-6.
116. Fang K, Johns R, Macdonald T, Kinter M, Gaston B. S-Nitrosoglutathione breakdown prevents airway smooth muscle relaxation in the guinea pig. Am J Physiol Lung Cell Mol Physiol 2000; 279: 716-21.
117. Matsumoto A, Comatas K, Liu L, Stamler J. Screening for nitric oxide-dependent protein-protein interactions. Science 2003; 301: 657-61.
118. Liu L, Hausladen A, Zeng M, Que L, Heitman J, Stamler J. A metabolic enzyme for S-nitrosothiol conserved from bacteria to humans. Nature 2001; 410: 490-6.
119. Nikitovic D, Holmgren A. S-Nitrosoglutathione is cleaved by the thioredoxin system with liberation of glutathione and redox regulating nitric oxide. J Biol Chem 1996; 271: 19180-5.
120. Johnson MA, Macdonald TL, Mannick JB, Conaway MR, Gaston B. Accelerated S-nitrosothiol breakdown by amyotrophic lateral sclerosis mutant copper, zinc-superoxide dismutase. J Biol Chem 2001; 276: 39872-8.
121. Askew S, Butler A, Flitney F, Kemp G, Megson I. Chemical mechanisms underlying the vasodilator and platelet antiaggregating properties of S-nitroso-N-acetyl-DL-penicillamine and S-nitrosoglutathione. Bioorganic Med Chem 1995; 3: 1-9.
122. Asano K, Chee C, Gaston, B, et al. Constitutive and induible nitric oxide synthase gene expression, regulation and activity in human lung epithelial cells. Proc Natl Acad Sci USA 1994; 91: 10089-93.
123. Gaston B, Sears S, Woods J, et al. Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure. Lancet 1998; 351: 1317-9.
124. Jain L, Brown LA, Eaton DC. Nitric oxide inhibits lung sodium transport through a cGMP-mediated inhibition of epithelial cation channels. Am J Physiol 1998; 274: 475-84.
125. Kamosinska B, Radomski MW, Duszyk M, Radomski A, Man SF. Nitric oxide activates chloride currents in human lung epithelial cells. Am J Physiol 1997; 272: 1098-104
126. Palmer L, Doctor A, Chhabra P, et al. S-Nitrosothiols signal hypoxia-mimetic vascular pathology. J Clin Invest 2007; 117: 2592-601.
127. Zaman K, Palmer L, Doctor A, Hunt J, Gaston B. Concentrationdependent effects of endogenous S-nitrosoglutathione on gene regulation by specificity proteins Sp3 and Sp1. Biochem J 2004; 380: 67-74.
128. Zaman K, Carraro S, Doherty J, et al. A novel class of compounds that increase CFTR expression and maturation in epithelial cells. Mol Pharmacol 2006; 70: 1435-42.
129. Zaman K, McPherson M, Vaughan J, et al. S-Nitrosoglutathione increases cystic fibrosis transmembrane regulator maturation. Biochem Biophys Res Commun 2001; 284: 65-70.
130. Marozkina N, Yemen S, Borowitz M, et al. Hsp70/Hsp90 organizing protein as a nitrosylation target in cystic fibrosis. Proc Natl Acad Sci USA 2010; 107: 11393-8.
131. Snyder A, McPherson ME, Hunt JF, Stamler JS, Gaston B. Acute effects of aerosolized S-nitrosoglutathione in cystic fibrosis. Am J Respir Crit Care Med 2002; 165: 1-5.
132. Chen L, Patel RP, Teng X, Bosworth CA, Lancaster JR Jr, Matalon S. Mechanisms of cystic fibrosis transmembrane conductance regulator activation by S-nitrosoglutathione. J Biol Chem 2006; 281: 9190-9.
133. Howard M, Fischer H, Roux J, et al. Mammalian osmolytes and SNitrosoglutathione promote F508 CFTR protein maturation and function. J Biol Chem 2003; 278: 35159-67.
134. Andersson C, Gaston B, Roomans G. S-Nitrosoglutathione induces functional fF508 CFTR in cultured airway epithelial cells. Biochem Biophys Res Comm 2002; 297: 552-7.
135. Servetnyk Z, Krujkova J, Gaston B, et al. Activation of delF508 CFTR in CF airway epithelial cell lines and CF nasal epithelial cells by S-nitrosoglutathione. Respir Res 2006; 7: 124-30.
136. Bannenberg G, Xue J, Engman L, Cotgreave I, Moldéus P, Ryrfeldt A. Characterization of bronchodilator effects and fate of Snitrosothiols in the isolated perfused and ventilated guinea pig lung. J Pharmacol Exp Therap 1995; 272: 1238-45.
137. Perkins W, Pabelick C, Warner DO, Jones KA. cGMP-independent mechanism of airway smooth muscle relaxation induced by S-nitrosoglutathione. Am J Physiol 1998; 275: 468-74.
138. Saura M, Zaragoza C, Quick RA, Hohenadl C, Lowenstein JM, Lowenstein CJ. An antiviral mechanism of nitric oxide: inhibition of a viral protease. Immunity 1999; 10: 21-6.
139. Degroote M, Testerman T, Yisheng X, Stauffer G, Fang F. Homocysteine antagonism of nitric oxide-related cytostasis in Salmonella typhimurium. Science 1996; 272: 414-7.
140. Morris S, Walsh R, Hansen J. Identification and characterization of some bacterial membrane sulfhydryl groups which are targets of bacteriostatic and antibiotic action. J Biol Chem 1984; 259: 13590-4.
141. Jain B, Rubinstein I, Robbins R, Leise K, Sisson J. Modulation of airway epithelial cell ciliary beat frequency by nitric oxide. Biochem Biophys Res Comm 1993; 191: 83-8.
142. Grasemann H, Gaston B, Fang K, Paul K, Ratjen F. Decreased levels of nitrosothiols in the lower airways of patients with cystic fibrosis and normal pulmonary function. J Pediatr 1999; 135: 770-2.
143. Zhang H, Schmidt BZ, Sun F, et al. Cysteine string protein monitors late steps in cystic fibrosis transmembrane conductance regulator giogenesis. J Biol Chem 2005; 281: 11312-21.
144. Zhang H, Schmidt BZ, Sun F, et al. Cysteine string protein monitors late steps in cystic fibrosis transmembrane conductance regulator biogenesis. J Biol Chem 2006; 281: 11312-21.
145. Chamberlain L, Burgoyne R. Cysteine-string protein: The chaperone at the synapse. J Neurochem 2000; 74: 1781-9.
146. Chamberlain LH, Burgoyne RD. Activation of the ATPase activity of heat-shock proteins Hsc70/Hsp70 by cysteine-string protein. Biochem J 1997; 322: 853-8.
147. Braun JE, Wilbanks SM, Scheller RH. The cysteine string secretory vesicle protein activates Hsc70 ATPase. J Biol Chem 1996; 271: 25989-93.
148. Meacham G, Patterson C, Zhang W, Younger J, Cyr D. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat Cell Biol 2001; 3: 100-5
149. Younger JM, Ren HY, Chen L, et al. A foldable CFTR ΔF508 biogenic intermediate accumulates upon inhibition of the Hsc70-CHIP E3 ubiquitin ligase. J Cell Biol 2004; 167: 1075-85.
150. Wilbanks SM, McKay DB. Structural replacement of active monovalent cations by the ε-amino group of lysine in the hATPase fragment of bovine Hsc70. Biochemistry 1998; 37: 7456-62.
151. Chen S, Sullivan W, Smith D. Differential inter-actions of p23 and the TPR-containing proteins Hop, cyp40, FKBP52 and FKBP51 with Hsp90 mutants. Cell Stress Chaperones 1998; 3: 118-29.
152. Carrigan P, Riggs D, Chinkers M, Smith D. Functional comparision of human and Drosophilia Hop reveals novel role in steroid receptor maturation. J Biol Chem 1998; 280: 8906-11.
153. Carrigan P, Sikkink L, Smith D, Ramirez-Alvardo M. Domain: domain interactions with Hop the Hsp70/Hsp90 organizing protein are required for protein stability and structure. Protein Sci 2006; 15: 522-32.